NCT05954312 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
Vividion Therapeutics, Inc.
Merck Sharp & Dohme LLC
Kyowa Kirin Co., Ltd.